All > Sickle Cell Disease > Paid Studies Indianapolis

Direct to Consumer for Sickle Cell Anemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sickle Cell AnemiaTypes of Telemedicine Delivery Models - Other
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will adapt and test two different types of telemedicine in order to improve care for children with sickle cell disease.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Imatinib Mesylate
1
FTX-6058 oral capsule(s)
1
PF-07209326

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Caregiver feedback
Measuring adherence to appointment in sickle cell care.
Measuring collaboration of primary care provider and subspecialty care provider.
Measuring healthcare utilization pre and post telemedicine participation.
Provider Feedback
6 months
Measuring adherence to lab draws in sickle cell care.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Imatinib Mesylate
1
FTX-6058 oral capsule(s)
1
PF-07209326

Trial Design

2 Treatment Groups

Direct to Consumer
1 of 2
Hub and Spoke
1 of 2

Active Control

60 Total Participants · 2 Treatment Groups

Primary Treatment: Direct to Consumer · No Placebo Group · N/A

Direct to Consumer
Other
ActiveComparator Group · 1 Intervention: Types of Telemedicine Delivery Models · Intervention Types: Other
Hub and Spoke
Other
ActiveComparator Group · 1 Intervention: Types of Telemedicine Delivery Models · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Indiana UniversityLead Sponsor
877 Previous Clinical Trials
759,495 Total Patients Enrolled
2 Trials studying Sickle Cell Anemia
395 Patients Enrolled for Sickle Cell Anemia
Seethal Jacob, MDPrincipal InvestigatorIndiana University

Eligibility Criteria

Age < 65 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must live within 1 hour of the pre-identified telemedicine sites.
Patients must be between 0 and 21 years old with Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top